Dose not stated; duration not stated. He used Aricept for his mother after a gradual decline in short-term memory. During the first week she had mild nausea, but after the treatment routine settled, she was more willing to join conversations and needed fewer reminders for familiar tasks.
3 Nov 2026
Aricept
Patients with Alzheimer’s disease and related dementia may be prescribed Aricept to support memory, attention, and everyday functioning. Aricept contains donepezil, a cholinesterase inhibitor that…
Patients with Alzheimer’s disease and related dementia may be prescribed Aricept to support memory, attention, and everyday functioning. Aricept contains donepezil, a cholinesterase inhibitor that increases acetylcholine activity in the brain. Its benefits are symptomatic and vary with disease stage and individual response.
Product information
Aricept contains donepezil hydrochloride and belongs to the cholinesterase inhibitor class. Donepezil is used for the symptomatic treatment of Alzheimer’s disease, the most common cause of dementia.
Ingredients
Aricept contains donepezil hydrochloride. Donepezil belongs to the cholinesterase inhibitor class and increases acetylcholine activity in the brain.
Therapeutic indications
Donepezil is used for the symptomatic treatment of Alzheimer’s disease, the most common cause of dementia. It may help preserve cognitive abilities and daily function for a period of time, although it does not remove the underlying amyloid plaques or stop the neurodegenerative process.
Eisai Inc. developed donepezil, which became one of the best-known oral treatments for Alzheimer’s dementia. Regulatory information from the United States Food and Drug Administration describes donepezil use across the clinical spectrum of Alzheimer’s disease, with treatment decisions based on the patient’s diagnosis, disease stage, tolerability, and response [1].
Primary indications for dementia management
Aricept may be considered when a clinician has diagnosed Alzheimer’s dementia and believes that cholinergic treatment could support cognition or daily activities. Typical treatment goals include:
- Maintaining memory and orientation for longer.
- Supporting attention and communication.
- Preserving everyday abilities such as dressing, eating, or handling familiar routines.
- Reducing the rate at which symptoms become more noticeable for some patients.
The response is not the same as a cure. Some people notice clearer thinking or improved participation in daily tasks, while others mainly experience a slower decline. Caregivers often provide the clearest observations because changes may be subtle and gradual.
Directions for use
- Dose: The amount of Aricept per intake is determined individually for each person.
- Frequency: Aricept is taken according to the prescribed treatment schedule.
- Timing: The timing of administration follows the prescribed schedule.
- Duration: Treatment continues while it provides suitable symptomatic benefit for the individual.
- Route: Aricept is taken by mouth.
Aricept contains donepezil hydrochloride, a cholinesterase inhibitor used for the symptomatic treatment of Alzheimer’s disease. It increases acetylcholine activity in the brain and may support memory, attention and everyday functioning, while its benefits vary with disease stage and individual response.
When not to use it
A prescriber needs a full medical history before treatment begins, especially where the following conditions apply:
- Previous allergy to donepezil, piperidine derivatives, or an excipient in the prescribed formulation.
- Slow heart rate, conduction disease, unexplained fainting, or recurrent falls.
- A history of stomach or duodenal ulcer, gastrointestinal bleeding, or regular use of ulcer-risk medicines.
- Asthma or chronic obstructive pulmonary disease.
- Seizure disorder.
- Urinary obstruction or difficulty passing urine.
- Significant liver impairment.
- Planned surgery requiring general anaesthesia.
Donepezil can increase vagal activity and may worsen bradycardia or conduction problems in susceptible patients. It can also increase gastrointestinal motility and acid secretion. People using medicines that slow the heart, including some beta blockers or selected antiarrhythmics, may require closer observation.
The medicine list should include antidepressants, antipsychotics, anticholinergic medicines, bladder treatments, anti-inflammatory drugs, sleep medicines, and supplements. Anticholinergic medicines can oppose donepezil’s intended cholinergic action. Medicines that increase bleeding risk may become more concerning in a person who develops vomiting, ulcer symptoms, or gastrointestinal bleeding.
When this is not for you
Aricept is NOT for you if you have an unexplained slow pulse, recurrent fainting, a serious allergy to donepezil, or another contraindication identified by a prescriber.
Pregnancy and breastfeeding are not typical treatment settings for Alzheimer’s disease, but exposure should be discussed promptly if pregnancy occurs or breastfeeding is being considered. Alcohol can worsen dizziness, impaired judgement, sleep problems, and falls.
Unwanted effects
The most frequent unwanted effects involve the digestive system and often appear after treatment begins or after the dose is increased. Nausea, vomiting, and diarrhoea are recognised adverse reactions to donepezil. Reduced appetite, weight loss, abdominal discomfort, and muscle cramps may also occur.
Many people tolerate these effects better after the body adjusts. Persistent vomiting or diarrhoea is different: it can cause dehydration, weakness, electrolyte disturbance, and falls, especially in older adults or people who already have limited mobility.
Gastrointestinal side-effect profile
| Reaction | Practical clinical meaning | When to seek prompt medical help |
|---|---|---|
| Nausea or reduced appetite | Food intake may fall during early treatment | Ongoing inability to eat or drink, marked weakness, or weight loss |
| Vomiting or diarrhoea | Fluid and electrolyte loss can occur | Repeated vomiting, blood in stool, severe abdominal pain, or dehydration |
| Abdominal discomfort | May accompany increased cholinergic activity | Severe, persistent, or worsening pain |
Common reactions can include:
- Nausea, vomiting, or diarrhoea.
- Headache, dizziness, or fatigue.
- Muscle cramps.
- Insomnia, vivid dreams, or unusual sleep disturbance.
- Reduced appetite and weight loss.
- Urinary frequency or occasional urinary incontinence.
Serious reactions require urgent medical assessment. These include fainting, a very slow pulse, new or worsening chest symptoms, seizures, severe allergic swelling, black stools, vomiting blood, or persistent severe abdominal pain.
A practical detail is easy to miss: dizziness may be more dangerous than it feels. In an older person, a short episode of light-headedness can lead to a fall, hip injury, or loss of confidence walking outdoors. Sleep disturbance also deserves attention because vivid dreams or insomnia can increase daytime confusion.
Mechanism of action
Donepezil works by inhibiting acetylcholinesterase, the enzyme that breaks down acetylcholine. Acetylcholine is a neurotransmitter involved in attention, learning, memory formation, and communication between nerve cells. By slowing its breakdown, donepezil increases cholinergic signalling in the central nervous system.
The effect is biochemical rather than structural. Donepezil does not rebuild damaged neurons, dissolve amyloid plaques, or reverse established brain changes associated with Alzheimer’s disease. Its purpose is to improve the efficiency of remaining cholinergic pathways.
Enzymatic inhibition and neurotransmitter preservation
A nerve cell releases acetylcholine into a synaptic space. The chemical then binds to receptors on a neighbouring cell and transmits a signal. Acetylcholinesterase rapidly terminates that signal by breaking acetylcholine down. Donepezil reduces this enzymatic breakdown, allowing acetylcholine to remain active for longer.
That action explains both the intended effects and several adverse reactions. Increased cholinergic activity in the brain may support attention, while increased cholinergic activity in the gastrointestinal tract can contribute to nausea, loose stools, abdominal discomfort, or vomiting. The relationship between cholinergic signalling and Alzheimer’s symptoms is described in the European Medicines Agency’s pharmacological information for donepezil-containing medicines [2].
Amyloid plaques are one of the pathological features associated with Alzheimer’s disease. Donepezil does not target amyloid directly. Its role is to influence neurotransmission despite the ongoing disease process.
Common mistakes
Poor outcomes can result from routine errors rather than a lack of pharmacological activity. The most frequent problems include:
- Increasing the amount without a planned titration schedule.
- Taking two doses after forgetting the previous one.
- Stopping suddenly after several months because improvement feels limited.
- Failing to report vomiting, diarrhoea, fainting, or significant weight loss.
- Giving the pill at an inconsistent time when several caregivers share responsibility.
- Crushing or altering a formulation without confirming that the specific tablet allows it.
- Continuing an old prescription after a clinician has changed the treatment plan.
- Treating a sudden change in confusion as normal disease progression.
A missed dose should not usually be replaced with an extra dose. The safest action depends on how long the treatment has been interrupted and the prescribed schedule. Longer gaps may require a clinician to reassess how treatment is restarted. The caregiver should record the missed dose and contact the prescriber when instructions are unclear. Restarting without advice can increase nausea, dizziness, or other adverse effects.
Another easy-to-miss issue is weight loss. A few days of low appetite may seem minor, but repeated poor intake can worsen weakness and confusion in older adults. Weighing the person periodically can provide useful information during treatment reviews.
Comparison
Donepezil, rivastigmine, and galantamine are cholinesterase inhibitors used in Alzheimer’s disease. They share a broad therapeutic aim but differ in pharmacology, dosage flexibility, routes of administration, and tolerability.
| Active ingredient | Main pharmacological distinction | Administration considerations |
|---|---|---|
| Donepezil | Predominantly inhibits acetylcholinesterase in the central nervous system | Oral treatment with a relatively convenient daily schedule |
| Rivastigmine | Inhibits acetylcholinesterase and butyrylcholinesterase | Oral and transdermal approaches may be used, with the patch sometimes helping patients who cannot tolerate oral treatment |
| Galantamine | Inhibits acetylcholinesterase and modulates nicotinic acetylcholine receptors | Oral treatment with dose adjustment and attention to gastrointestinal tolerability |
The choice depends on the patient’s symptoms, swallowing ability, other medicines, kidney or liver function, adherence pattern, and previous adverse reactions. Donepezil may suit a person who benefits from a simple oral routine. Rivastigmine can be considered when a transdermal route is clinically preferable, while galantamine has an additional action at nicotinic receptors.
Switching between these medicines should be planned. Starting the replacement too soon, stopping both for an extended period, or using overlapping treatment without a clear instruction can increase adverse effects and make the clinical response difficult to judge.
What doctors say
In clinical practice, doctors usually set modest treatment goals. The aim is often to preserve an existing ability for longer rather than produce a dramatic return of memory. A caregiver’s observations can be as valuable as a brief consultation because daily changes may appear first during meals, conversations, bathing, or familiar household tasks.
Treatment reviews commonly consider:
- Whether memory, attention, or daily activities have stabilised.
- Whether adverse effects are affecting nutrition, sleep, mobility, or mood.
- Whether the person can take pills reliably.
- Whether another illness or medicine could explain a sudden decline.
- Whether continuing treatment remains consistent with the patient’s care goals.
The Australian Therapeutic Goods Administration provides medicine safety information relevant to older adults, including the need to consider cardiovascular, gastrointestinal, neurological, and urinary effects when prescribing medicines such as donepezil [3]. A sudden deterioration should not automatically be attributed to Alzheimer’s disease. Infection, dehydration, constipation, pain, sleep loss, or a new medicine can produce delirium.
One clinical nuance matters: a lack of obvious improvement does not always mean the treatment has failed. A patient may be maintaining conversation or eating independently when the untreated course would have involved a faster loss of those abilities. Assessment should compare function over time, not rely on one good or bad day.
What customers often ask
What should be discussed with a doctor before starting Aricept?
The prescriber should review fainting, slow pulse, heart rhythm disorders, ulcers, gastrointestinal bleeding, seizures, asthma, urinary obstruction, liver disease, and upcoming anaesthesia. A complete list of prescription medicines, over-the-counter products, and supplements is also relevant because anticholinergic and heart-rate-lowering medicines can affect treatment. The FDA prescribing information updated in 2019 describes these precaution areas for donepezil and supports an individualised assessment before treatment begins [4].
What happens after stopping Aricept, and does it need tapering?
Stopping can remove the symptomatic cholinergic support that was helping cognition or daily function, and decline may become more noticeable after treatment is withdrawn. Whether tapering is needed depends on the treatment duration, reason for stopping, current dose, adverse effects, and the patient’s clinical condition. A planned interruption is preferable to an abrupt change when there is no urgent safety problem. NICE dementia guidance from 2018 supports reviewing cognitive medicines according to benefit, adverse effects, and the person’s care goals.
Can Aricept be combined with anticholinergic medicines or supplements?
Anticholinergic medicines used for bladder symptoms, allergies, motion sickness, or sleep can reduce cholinergic activity and may counteract some of donepezil’s effects. Some supplements can also cause dizziness, sedation, bleeding concerns, or gastrointestinal upset, which may be mistaken for a direct donepezil reaction. A medicine review should identify the exact product and dose before combining treatments. The EMA product information for donepezil, updated in 2023, describes pharmacodynamic interactions involving cholinergic and anticholinergic medicines.
What should happen after a missed dose?
Do not automatically take two doses to compensate for a missed one. If the next scheduled dose is approaching, the prescriber’s missed-dose plan should determine whether the omitted dose is skipped. A longer interruption can be different from one late dose because restarting may require renewed titration. The Australian TGA medicine information for donepezil, updated in 2024, advises care after treatment interruptions, especially when several days have passed.
Is alcohol allowed while using Aricept?
Alcohol may increase dizziness, drowsiness, poor coordination, and the risk of falls. It can also worsen sleep disruption and make it harder for caregivers to judge whether confusion reflects the illness, the medicine, or intoxication. Older adults and people with balance problems are more vulnerable to these effects. WHO alcohol guidance published in 2023 supports avoiding alcohol when it worsens medication-related impairment or creates a safety risk.
Do you offer anonymous delivery?
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Comparison
Sources
- U.S. Food and Drug Administration (2019). Aricept (donepezil hydrochloride) Prescribing Information
- European Medicines Agency (2023). Donepezil-containing medicinal products: product information
- Therapeutic Goods Administration (2024). Donepezil: Australian medicine safety information
- World Health Organization (2020). WHO Expert Committee on Specifications for Pharmaceutical Preparations: good storage and distribution practices for medical products
How Buyers Rate Aricept
Based on 4 reviews
Dose not stated; duration: about three months. He helped his father take the pills for about three months. The daily routine was manageable, although vivid dreams and reduced appetite became troublesome after a dose increase, so the family arranged an earlier treatment review.
About three months 5 Oct 2026Dose not stated; duration: several months. He described a modest benefit rather than a dramatic change. After several months, he still forgot appointments, but he was able to follow his morning routine more independently and remained socially engaged.
Several months 21 Oct 2026Dose not stated; duration: several days. He stopped treatment after diarrhoea continued for several days and did not realise that dehydration could worsen confusion. After medical review and a revised plan, the family paid closer attention to fluids, bowel symptoms, and dose timing.
Several days 14 Oct 2026